Efficacy and safety of first‐line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study

To investigate the efficacy and safety of first‐line nivolumab plus ipilimumab for patients treated with metastatic renal cell carcinoma.

[1]  M. Akiyama,et al.  Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study , 2020, Journal for ImmunoTherapy of Cancer.

[2]  T. Habuchi,et al.  Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes , 2020, International Journal of Clinical Oncology.

[3]  M. Kanehira,et al.  Inflammatory markers for predicting responses to nivolumab in patients with metastatic renal cell carcinoma , 2020, International journal of urology : official journal of the Japanese Urological Association.

[4]  Kazuhiko Yoshida,et al.  Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. , 2019, Urologic oncology.

[5]  Douglas B. Johnson,et al.  Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[6]  C. Porta,et al.  Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. , 2019, European urology.

[7]  R. Motzer,et al.  Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up , 2019, Japanese journal of clinical oncology.

[8]  C. Porta,et al.  Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[9]  T. Habuchi,et al.  Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study. , 2019, Clinical genitourinary cancer.

[10]  C. Ohyama,et al.  C‐reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma , 2019, International journal of urology : official journal of the Japanese Urological Association.

[11]  K. Harada,et al.  C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab , 2019, International Journal of Clinical Oncology.

[12]  K. Ito.  Recent advances in the systemic treatment of metastatic non‐clear cell renal cell carcinomas , 2019, International journal of urology : official journal of the Japanese Urological Association.

[13]  C. Ohyama,et al.  Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma. , 2019, Clinical genitourinary cancer.

[14]  T. Nakayama,et al.  Immunotherapy for genitourinary tumors , 2019, International journal of urology : official journal of the Japanese Urological Association.

[15]  K. Harada,et al.  Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan , 2018, International journal of urology : official journal of the Japanese Urological Association.

[16]  D. Ye,et al.  Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma , 2018, International journal of urology : official journal of the Japanese Urological Association.

[17]  E. Oki,et al.  C‐reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer , 2018, Journal of gastroenterology and hepatology.

[18]  K. Nakano,et al.  Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study , 2018, International journal of urology : official journal of the Japanese Urological Association.

[19]  R. Figlin,et al.  Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group , 2018, Clinical genitourinary cancer.

[20]  E. Kikuchi,et al.  Prognostic Value of Baseline Serum C‐Reactive Protein Level in Intermediate‐Risk Group Patients With Metastatic Renal‐Cell Carcinoma Treated by First‐Line Vascular Endothelial Growth Factor–Targeted Therapy , 2018, Clinical genitourinary cancer.

[21]  T. Nakatani,et al.  The difference in the survival rate of patients with metastatic renal cell carcinoma in the intermediate-risk group of the Memorial Sloan Kettering Cancer Center criteria , 2018, Oncotarget.

[22]  S. Park,et al.  Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first‐line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma , 2018, International journal of urology : official journal of the Japanese Urological Association.

[23]  A. Matsubara,et al.  Editorial Comment from Dr Teishima and Dr Matsubara to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first‐line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma , 2018, International journal of urology : official journal of the Japanese Urological Association.

[24]  R. Figlin,et al.  Heterogeneity of Patients With Intermediate‐Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib , 2017, Clinical genitourinary cancer.

[25]  N. Vogelzang,et al.  Axitinib Versus Sorafenib in First‐Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial , 2017, Clinical genitourinary cancer.

[26]  K. Harada,et al.  Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second‐Line Therapy for Metastatic Renal‐Cell Carcinoma: Experience in Real‐World Clinical Practice in Japan , 2017, Clinical genitourinary cancer.

[27]  H. Akiyama.  Japan's longevity challenge , 2015, Science.

[28]  N. Vogelzang,et al.  Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. , 2013, The Lancet. Oncology.

[29]  Y. Tomita,et al.  Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. , 2010, European urology.

[30]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.